| Literature DB >> 28520718 |
Satya Krishna Ramachandran1, Aleda Thompson2, Jaideep J Pandit3, Scott Devine4, Amy M Shanks2.
Abstract
INTRODUCTION: The clinical importance of postoperative episodic hypoxemia is still unclear, and therefore largely under-studied. As a result, there is limited understanding of its relationship with early postoperative respiratory complications (PRC, defined as intubation within three days of surgery) and hospital resource utilization.Entities:
Mesh:
Year: 2017 PMID: 28520718 PMCID: PMC5435138 DOI: 10.1371/journal.pone.0175408
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Study flow showing inclusions and exclusions.
Frequency distribution of study variables across outcome groups.
| Variable | No early PRC N = 125,389 | Early PRC N = 351 | p-value | Odds Ratio (95% CI) | % Missing |
|---|---|---|---|---|---|
| Nadir desaturation <89% | 17,895 (16) | 111 (37) | <0.001 | 3.2 (2.5–4.1) | 7.9 |
| Median SpO2 <94% | 18,207 (16) | 61 (21) | 0.037 | 1.4 (1.0–1.8) | 11.3 |
| Duration >18 min of SpO2 <94% | 13,335 (13) | 73 (26) | <0.001 | 2.3 (1.8–3.0) | 18.2 |
| PACU oxygen treatment duration quartiles | <0.001 | N/A | |||
| <30 minutes | 27,614 (26) | 18 (7) | |||
| 31–60 minutes | 26,198 (25) | 56 (21) | |||
| 61–90 minutes | 26,278 (25) | 92 (35) | |||
| >90 minutes | 26,841 (25) | 99 (37) | |||
| <0.001 | N/A | 6.6 | |||
| Low Risk | 56,286 (48) | 103 (32) | |||
| Moderate Risk | 51,306 (44) | 162 (51) | |||
| High Risk | 9,261 (8) | 53 (17) | |||
| Smoking | 16,302 (13) | 56 (16) | 0.108 | 1.3 (1.0–1.7) | 0 |
| Alcohol intake | 8,898 (7) | 30 (9) | 0.298 | 1.2 (0.8–1.8) | 0 |
| Myocardial infarction | 89 (0) | 1 (0) | 0.223 | 4.0 (0.6–30.0) | 0 |
| COPD | 6,979 (6) | 52 (15) | <0.001 | 3.0 (2.2–4.0) | 0 |
| Liver disease | 7,626 (6) | 37 (11) | 0.001 | 1.8 (1.3–2.6) | 0 |
| Renal disease | 10,670 (9) | 70 (20) | <0.001 | 2.7 (2.1–3.5) | 0 |
| Congestive heart failure | 3,664 (3) | 26 (7) | <0.001 | 2.7 (1.8–4.0) | 0 |
| Neurological disease | 16,861 (13) | 68 (19) | 0.002 | 1.5 (1.2–2.0) | 0 |
| Seizures | 3,863 (3) | 15 (4) | 0.151 | 1.5 (0.9–2.5) | 0 |
| Cancer | 34,951 (28) | 112 (32) | 0.094 | 1.2 (1.0–1.5) | 0 |
| Steroid treatment | 5,049 (4) | 36 (10) | <0.001 | 2.7 (1.9–3.9) | 0 |
| Pneumonia | 4,150 (3) | 31 (9) | <0.001 | 2.8 (2.0–4.1) | 0 |
| Pulmonary hypertension | 1,654 (1) | 13 (4) | 0.001 | 2.9 (1.7–5.0) | 0 |
| Coma | 914 (1) | 5 (1) | 0.117 | 2.0 (0.8–4.8) | 0 |
| Sepsis | 959 (1) | 9 (3) | 0.002 | 3.4 (1.8–6.6) | 0 |
| ASA physical status | <0.001 | 4.1 (2.9–5.7) | 0.7 | ||
| Class 1, 2 or 3 | 120,717 (97) | 305 (89) | |||
| Class 4 or 5 | 3,799 (3) | 39 (11) | |||
| Pre-operative Opioid | 31,604 (25) | 103 (29) | 0.083 | 1.2 (1.0–1.6) | 0 |
| Pre-operative Benzodiazepine | 14,085 (11) | 51 (15) | 0.059 | 1.3 (1.0–1.8) | 0 |
| <0.001 | N/A | ||||
| Outpatient | 64,047 (51) | 87 (25) | |||
| Admit on day of surgery | 45,458 (36) | 160 (46) | |||
| Preoperative admission | 15,884 (13) | 104 (30) | |||
| Anesthesia duration ≥ 75th centile | 36,562 (29) | 190 (54) | <0.001 | 2.9 (2.3–3.5) | 0 |
| Intraoperative aminoglycoside | 12,953 (10) | 45 (13) | 0.132 | 1.3 (0.9–1.7) | 0 |
| Duration of MAC above 1 ≥ 75th centile | 58,563 (47) | 91 (26) | <0.001 | 0.4 (0.3–0.5) | 0 |
| <0.001 | N/A | ||||
| No NMBA administered | 49,612 (39) | 62 (18) | |||
| NMB with reversal agent administration | 74,899 (60) | 285 (81) | |||
| NMB without reversal agent administration | 878 (1) | 4 (1) | |||
| Cisatracurium | 7,331 (6) | 25 (7) | 0 | ||
| Rocuronium | 5,616 (5) | 35 (10) | 0 | ||
| Vecuronium | 62,830 (50) | 229 (65) | 0 | ||
| NMBA dose ≥75th centile | 19,047 (15) | 47 (13) | 0.371 | 0.9 (0.6–1.2) | 0 |
| High dose Cisatracurium | 1,805 (1) | 5 (1) | 0.999 | 1.0 (0.4–2.4) | 0 |
| High dose Vecuronium | 16,381 (13) | 43 (12) | 0.686 | 0.9 (0.7–1.3) | 0 |
| High dose Rocuronium | 1,278 (1) | 13 (4) | <0.001 | 3.7 (2.1–6.5) | 0 |
| Any TOF use | 46,318 (37) | 164 (47) | <0.001 | 1.5 (1.2–1.8) | 0 |
| PRBC administration | 1,944 (2) | 17 (5) | <0.001 | 3.2 (2.0–5.3) | 0 |
| FFP administration | 496 (0) | 3 (1) | 0.164 | 2.2 (0.7–6.8) | 0 |
| Fentanyl | 116,880 (93) | 310 (88) | 0.001 | 0.6 (0.4–0.8) | 0 |
| Hydromorphone | 5,655 (5) | 17 (5) | 0.714 | 1.1 (0.7–1.8) | 0 |
| Morphine | 33,393 (27) | 100 (29) | 0.433 | 1.1 (0.9–1.4) | 0 |
| 0.275 | 1.2 (0.8–1.7) | 0 | |||
| General Anesthesia | 114,911 (92) | 316 (90) | |||
| General + Regional Anesthesia | 10,478 (8) | 35 (10) | |||
| <0.001 | N/A | 0.6 | |||
| Propofol Infusion | 16,415 (13) | 27 (8) | |||
| Volatile Anesthetic | 96,861 (77) | 205 (58) | |||
| Combined propofol infusion and volatile anesthetic | 11,335 (9) | 119 (34) | |||
| 0.006 | N/A | 0 | |||
| 0 | 5,278 (4) | 25 (7) | |||
| 1 | 78,281 (62) | 189 (54) | |||
| 2 | 40,518 (32) | 133 (38) | |||
| 3 | 1,302 (1) | 4 (1) | |||
| 4 | 10 (0) | 0 (0) | |||
| Intraoperative morphine equivalents ≥ 75th centile | 13,659 (11) | 16 (5) | <0.001 | 0.4 (0.2–0.6) | 0 |
| Naloxone | 747 (1) | 19 (5) | <0.001 | 9.5 (6.0–15.2) | 0 |
| PCA | 170 (0) | 5 (1) | <0.001 | 10.6 (4.3–26.1) | 0 |
| High risk surgery | 48,238 (39) | 197 (56) | <0.001 | 2.0 (1.7–2.5) | 0.5 |
Interaction between PSAP score and surgical risk.
| Nadir desaturation | Lower risk surgery | Higher risk surgery | ||
|---|---|---|---|---|
| AOR | p-value | AOR | p-value | |
| <89% | 0.9 [0.6, 1.2] | 0.467 | 1.7 [1.2, 2.4] | 0.006 |
| ≥89% | 0.3 [0.2, 0.4] | <0.001 | 0.5 [0.4, 0.8] | <0.001 |
Estimates are from a logistic regression model exploring the interaction between nadir desaturation and surgical risk.
Independent predictors of early postoperative tracheal intubation–Higher surgical risk.
| AOR | 95% C.I. | p-value | ||
|---|---|---|---|---|
| Lower | Upper | |||
| Nadir Desaturation <10th centile | 2.0 | 1.4 | 3.0 | <0.001 |
| <30 minutes | ||||
| 31–60 minutes | 1.9 | 0.7 | 4.8 | 0.180 |
| 61–90 minutes | 2.5 | 1.0 | 6.3 | 0.048 |
| >90 minutes | 3.2 | 1.3 | 7.9 | 0.012 |
| Low risk (PSAP 1–3) Baseline | ||||
| Moderate risk (PSAP 4–5) | 2.3 | 1.4 | 3.6 | <0.001 |
| High risk (PSAP >5) | 2.3 | 1.2 | 4.3 | 0.009 |
| COPD | 2.5 | 1.6 | 3.9 | <0.001 |
| Renal disease | 1.7 | 1.1 | 2.7 | 0.019 |
| Steroid treatment | 1.9 | 1.2 | 2.9 | 0.049 |
| Outpatient Baseline | ||||
| Admit on day of surgery | 0.8 | 0.5 | 1.4 | 0.510 |
| Preoperative admission | 1.4 | 0.8 | 2.6 | 0.236 |
| Anesthesia duration ≥ 75th centile | 1.9 | 1.2 | 2.9 | 0.005 |
| ≥ 75th centile of duration of MAC above 1 | 0.4 | 0.3 | 0.7 | <0.001 |
| Reversal use | 2.6 | 1.4 | 4.8 | 0.003 |
| Number of intravenous opioids | 0.7 | 0.5 | 0.9 | 0.019 |
| Patient controlled analgesia | 10.5 | 3.0 | 36.7 | <0.001 |
| Naloxone administration | 8.5 | 4.0 | 18.0 | <0.001 |
| Propofol Infusion (Baseline) | ||||
| Volatile Anesthetic | 0.2 | 0.1 | 0.4 | <0.001 |
| Combined propofol infusion and volatile anesthetic | 1.0 | 0.5 | 2.1 | 0.897 |
| Anesthesia Technique General + Regional | 0.5 | 0.3 | 1.0 | 0.059 |
Variables dropped by the model included neurological disease, pneumonia, pulmonary hypertension, sepsis, ASA status, use or non-use of NMBA, morphine equivalent dose, TOF use, high dose rocuronium, admit type and number of PRBCs.
Independent predictors of early postoperative tracheal intubation—Lower surgical risk.
| AOR | 95% C.I. | p-value | ||
|---|---|---|---|---|
| Lower | Upper | |||
| Nadir Desaturation 10th centile | 2.1 | 1.4 | 3.1 | 0.001 |
| <30 minutes | ||||
| 31–60 minutes | 2.0 | 0.9 | 4.2 | 0.069 |
| 61–90 minutes | 3.0 | 1.5 | 6.2 | 0.003 |
| >90 minutes | 3.0 | 1.4 | 6.2 | 0.003 |
| Renal disease | 2.6 | 1.6 | 4.2 | <0.001 |
| Outpatient Baseline | ||||
| Admit on day of surgery | 1.1 | 0.7 | 1.8 | 0.661 |
| Preoperative admission | 1.9 | 1.1 | 3.3 | 0.028 |
| Anesthesia duration ≥ 75th centile | 2.6 | 1.7 | 4.0 | <0.001 |
| ≥ 75th centile of duration of MAC above 1 | 0.6 | 0.4 | 0.9 | 0.006 |
| Propofol Infusion (Baseline) | ||||
| Volatile Anesthetic | 0.8 | 0.4 | 1.7 | 0.598 |
| Combined propofol infusion and volatile anesthetic | 2.8 | 1.3 | 5.9 | 0.008 |
| High dose Rocuronium | 5.2 | 2.1 | 12.4 | <0.001 |
Variables dropped by the model included PSAP risk, COPD, liver disease, congestive heart failure, neurological disease, steroid treatment, pneumonia, pulmonary hypertension, sepsis, ASA status, reversal use, PCA use, naloxone use, number of opioids, morphine equivalent dose, TOF use,number of PRBCs, and NMB administered.
Unmatched and matched univariates.
| Unmatched (N = 107,196) | Matched (N = 37,354) | |||||
|---|---|---|---|---|---|---|
| Risk for OSA (PSAP categories) | <0.001 | 0.276 | ||||
| Low Risk | 31,311 (42) | 17,459 (66) | 11,149 (60) | 11,014 (59) | ||
| Moderate Risk | 35,814 (48) | 8,044 (31) | 6,776 (36) | 6,925 (37) | ||
| High Risk | 7,124 (10) | 762 (3) | 752 (4) | 738 (4) | ||
| COPD | 5,078 (6) | 651 (2) | <0.001 | 517 (3) | 548 (3) | 0.335 |
| Liver Disease | 4,804 (6) | 957 (3) | <0.001 | 800 (4) | 786 (4) | 0.719 |
| Renal Disease | 7,701 (10) | 1,099 (4) | <0.001 | 974 (5) | 961 (5) | 0.762 |
| Congestive Heart Failure | 2,653 (3) | 255 (1) | <0.001 | 248 (1) | 233 (1) | 0.491 |
| Neurological Disease | 11,712 (15) | 2,261 (8) | <0.001 | 1,792 (10) | 1,754 (9) | 0.502 |
| Steroid Treatment | 3,484 (4) | 621 (2) | <0.001 | 583 (3) | 532 (3) | 0.121 |
| Pneumonia | 2,775 (3) | 482 (2) | <0.001 | 398 (2) | 387 (2) | 0.692 |
| Pulmonary Hypertension | 1,195 (2) | 127 (0) | <0.001 | 132 (1) | 117 (1) | 0.340 |
| Sepsis | 620 (1) | 101 (0) | <0.001 | 90 (0) | 87 (0) | 0.821 |
| ASA physical status | <0.001 | 0.684 | ||||
| Class 1, 2 or 3 | 76,448 (97) | 27,277 (99) | 18,478 (99) | 18,486 (99) | ||
| Class 4 or 5 | 2,580 (3) | 218 (1) | 199 (1) | 191 (1) | ||
| <0.001 | 0.020 | |||||
| Outpatient | 31,195 (39) | 22,854 (83) | 14,079 (75) | 14,302 (77) | ||
| Admit on day of surgery | 37,484 (47) | 3,526 (13) | 3,466 (19) | 3,270 (18) | ||
| Preoperative admission | 10,885 (14) | 1,252 (5) | 1,132 (6) | 1,105 (6) | ||
| ≥ 75th centile | 28,233 (35) | 3,594 (13) | <0.001 | 3,093 (17) | 3,023 (16) | 0.328 |
| <0.001 | 0.025 | |||||
| Propofol Infusion | 5,878 (7) | 9,387 (34) | 3,918 (21) | 3,707 (20) | ||
| Volatile Anesthetic | 66,213 (84) | 15,559 (57) | 12,877 (69) | 13,046 (70) | ||
| Combined propofol infusion and volatile anesthetic | 7,123 (9) | 2,498 (9) | 1,882 (10) | 1,924 (10) | ||
| ≥ 75th centile | 36,822 (46) | 13,960 (51) | <0.001 | 9,060 (49) | 9,111 (49) | 0.600 |
| <0.001 | 0.306 | |||||
| No NMBA used | 24,585 (31) | 16,053 (58) | 9,641 (52) | 9,669 (52) | ||
| Cisatracurium | 5,298 (7) | 584 (2) | 575 (3) | 524 (3) | ||
| Rocuronium | 2,740 (3) | 1,660 (6) | 917 (5) | 964 (5) | ||
| Vecuronium | 46,941 (59) | 9,335 (34) | 7,544 (40) | 7,520 (40) | ||
| Reversal use | 53,104 (67) | 10,763 (39) | <0.001 | 8,532 (46) | 8,487 (45) | 0.640 |
| PRBC Administration | 1,282 (2) | 83 (0) | <0.001 | 80 (0) | 75 (0) | 0.687 |
| Fentanyl | 74,785 (94) | 25,321 (92) | <0.001 | 17,301 (93) | 17,319 (93) | 0.721 |
| Naloxone | 603 (1) | 69 (0) | <0.001 | 54 (0) | 52 (0) | 0.846 |
| <0.001 | <0.001 | |||||
| 0 | 2,646 (3) | 1,653 (6) | 966 (5) | 879 (5) | ||
| 1 | 43,866 (55) | 21,234 (77) | 13,680 (73) | 13,933 (75) | ||
| 2 | 32,065 (40) | 4,562 (17) | 3,940 (21) | 3,715 (20) | ||
| 3 | 981 (1) | 181 (1) | 90 (0) | 149 (1) | ||
| 4 | 6 (0) | 2 (0) | 1 (0) | 1 (0) | ||
| ≥ 75th centile | 8,167 (10) | 3,637 (13) | <0.001 | 2,484 (13) | 2,503 (13) | 0.773 |
| PCA | 115 (0) | 7 (0) | <0.001 | 10 (0) | 6 (0) | 0.317 |
| TOF use | 7,180 (9) | 1,291 (5) | <0.001 | 1,143 (6) | 1,125 (6) | 0.697 |
| High Dose Rocuronium | 717 (1) | 306 (1) | 0.002 | 187 (1) | 207 (1) | 0.311 |
| Head | 8,661 (11) | 3,259 (12) | <0.001 | 2,396 (13) | 2,497 (13) | 0.121 |
| Neck | 8,986 (11) | 1,756 (6) | <0.001 | 1,517 (8) | 1,494 (8) | 0.662 |
| Thorax (Chest wall and shoulder girdle) | 5,226 (7) | 3,256 (12) | <0.001 | 1,968 (11) | 1,949 (10) | 0.748 |
| Intrathoracic | 2,632 (3) | 153 (1) | <0.001 | 161 (1) | 141 (1) | 0.248 |
| Spine and spinal cord | 3,249 (4) | 301 (1) | <0.001 | 288 (2) | 280 (2) | 0.735 |
| Upper abdomen | 9,033 (11) | 1,272 (5) | <0.001 | 1,063 (6) | 1,086 (6) | 0.609 |
| Lower abdomen | 12,358 (16) | 3,112 (11) | <0.001 | 2,304 (12) | 2,293 (12) | 0.863 |
| Perineum | 9,284 (12) | 4,701 (17) | <0.001 | 3,346 (18) | 3,348 (18) | 0.979 |
| Pelvis (except hip) | 411 (1) | 92 (0) | <0.001 | 76 (0) | 78 (0) | 0.872 |
| Upper leg (except knee) | 3,497 (4) | 609 (2) | <0.001 | 453 (2) | 461 (2) | 0.789 |
| Knee and popliteal area | 2,778 (3) | 2,611 (9) | <0.001 | 987 (5) | 941 (5) | 0.282 |
| Lower leg (below knee, including ankle and foot) | 2,937 (4) | 1,430 (5) | <0.001 | 918 (5) | 898 (5) | 0.630 |
| Shoulder and axilla | 2,754 (3) | 2,607 (9) | <0.001 | 1,377 (7) | 1,371 (7) | 0.905 |
| Upper arm and elbow | 638 (1) | 303 (1) | <0.001 | 220 (1) | 209 (1) | 0.593 |
| Forearm, wrist and hand | 1,477 (2) | 816 (3) | <0.001 | 519 (3) | 546 (3) | 0.401 |
| Radiological procedure | 3,108 (4) | 540 (2) | <0.001 | 465 (2) | 460 (2) | 0.868 |
| Burn excisions or debridement | 228 (0) | 46 (0) | <0.001 | 44 (0) | 39 (0) | 0.583 |
| Obstetric | 108 (0) | 117 (0) | <0.001 | 80 (0) | 92 (0) | 0.359 |
| Other procedure | 57 (0) | 10 (0) | 0.042 | 13 (0) | 5 (0) | 0.059 |
| Missing | 2,142 (3) | 641 (2) | <0.001 | 482 (3) | 489 (3) | 0.820 |
Secondary outcomes on matched dataset.
| Oxygen treatment duration≤30 minutes (N = 18,677) | p-value | ||
|---|---|---|---|
| Charge (median, 25th, 75th centile) | 12,532 [8,683 to 21,690] | 10,874 [7,661 to 18,190] | <0.001 |
| Charge (median, 25th, 75th centile) | 9,749 [5,001 to 15,076] | 8,672 [4,623 to 13,370] | <0.001 |
| Charge (median, 25th, 75th centile) | 6,075 [0 to 10,508] | 6,205 [0 to 10,162] | <0.001 |
| Charge (median, 25th, 75th centile) | 0 [0 to 370] | 0 [0 to 125] | <0.001 |
| 0 [0 to 1] | 0 [0 to 1] | <0.001 | |
| Reintubation [n(%)] | 34 (0) | 15 (0) | 0.007 |
| Ventilatory support [n(%)] | 551 (3) | 131 (1) | <0.001 |
All data are reported as either frequency (percent) or median [25th percentile to 75th percentile], as appropriate.
Total charge data across PACU oxygen therapy quartiles.
| PACU oxygen therapy quartiles | Unmatched cohort—total charges in dollars | ||||
| Median | Percentile 25 | Percentile 75 | Valid N | Total N | |
| <30 minutes | 10187.00 | 7360.05 | 15652.60 | 20671 | 27632 |
| 31–60 minutes | 20354.00 | 11375.55 | 40504.46 | 22037 | 26254 |
| 61–90 minutes | 23955.77 | 12646.31 | 42348.34 | 23128 | 26370 |
| >90 minutes | 23814.44 | 13454.05 | 39598.41 | 24344 | 26940 |
| Matched cohort—total charges in dollars | |||||
| Median | Percentile 25 | Percentile 75 | Valid N | Total N | |
| <30 minutes | 10873.85 | 7660.74 | 18189.16 | 14499 | 18677 |
| 31–60 minutes | 12054.95 | 8639.41 | 18706.39 | 5594 | 7472 |
| 61–90 minutes | 12678.46 | 8767.35 | 23374.65 | 4715 | 6053 |
| >90 minutes | 13203.71 | 8613.03 | 24989.58 | 4164 | 5152 |